中国肺癌杂志2025，Vol.28Issue(7)：487-496,10.DOI:10.3779/j.issn.1009-3419.2025.106.18
新辅助靶向治疗在EGFR突变可手术切除肺腺癌患者中的应用价值
Application Value of Neoadjuvant Targeted Therapy in Patients with EGFR-mutant Resectable Lung Adenocarcinoma
摘要
Abstract
Background and objective The proportion of patients with non-small cell lung cancer(NSCLC)har-boring epidermal growth factor receptor(EGFR)mutations is relatively high in China.However,these patients currently lack significant benefits from available neoadjuvant treatment options.This study aims to explore the potential application value of neoadjuvant targeted therapy by evaluating its efficacy and safety in patients with EGFR-mutant resectable lung adenocarcino-ma.Methods A multicenter retrospective study was used to analyze the treatment effect of patients with stage ⅡA-ⅢB EGFR-mutant lung adenocarcinoma who underwent surgical resection after receiving neoadjuvant targeted therapy from July 2019 to October 2024.Results A total of 24 patients with EGFR-mutant lung adenocarcinoma from three centers were included in this study.All patients successfully underwent surgery and achieved R0 resection of 100.0%.The objective response rate(ORR)was 83.3%(20/24).The major pathologic response(MPR)rate was 37.5%(9/24),with 2 patients(8.3%)achieving pathological complete response(pCR).During neoadjuvant therapy,13 out of 24 patients(54.2%)experienced adverse events of grade 1-2,with no occurrences of≥grade 3.The most common treatment-related adverse events were rash(n=4,16.7%),mouth sores(n=2,8.3%),and diarrhea(n=2,8.3%).The median follow-up time was 33.0 months,no deaths occurred in all patients,and the overall survival(OS)rate was 100.0%.The 1-year disease-free survival(DFS)rate was 91.1%,and the 2-year DFS rate remained at 86.2%.Conclusion The application of neoadjuvant targeted therapy in patients with EGFR-mutant resectable lung adeno-carcinoma is safe and feasible,and is expected to become a highly promising neoadjuvant treatment option for the patients with EGFR-mutant lung adenocarcinoma.关键词
肺肿瘤/新辅助靶向治疗/表皮生长因子受体/主要病理缓解Key words
Lung neoplasms/Neoadjuvant targeted therapy/Epidermal growth factor receptor/Major pathologic response引用本文复制引用
黄世杰,谢金标,范梦颖,彭凯明,闫万璞,陈博扬,王武,杨天宝,陈克能,康明强..新辅助靶向治疗在EGFR突变可手术切除肺腺癌患者中的应用价值[J].中国肺癌杂志,2025,28(7):487-496,10.基金项目
本研究受莆田学院科研项目(No.2019093)资助 This study was supported by the grant from Scientific Research Project of Putian University(No.2019093) （No.2019093）
